{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:37:42Z","timestamp":1747157862369,"version":"3.40.5"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.clml.2019.11.015","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T14:08:04Z","timestamp":1577801284000},"page":"e144-e153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea Therapy"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3499-0607","authenticated-orcid":false,"given":"Jameel","family":"Al-Ghazaly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waled","family":"Al-Dubai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousr","family":"Noaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munasser","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Al-Gharasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.11.015_bib1","series-title":"Williams Hematology","first-page":"1437","article-title":"Chronic myelogenous leukemia and related disorders","author":"Liesveld","year":"2016"},{"key":"10.1016\/j.clml.2019.11.015_bib2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1365-2141.2000.02216.x","article-title":"Chronic myeloid leukemia","volume":"111","author":"Lee","year":"2000","journal-title":"Br J Hematol"},{"key":"10.1016\/j.clml.2019.11.015_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.11.015_bib4","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"European Leukemia Net. Chronic myeloid leukemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.11.015_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00000421-198206000-00013","article-title":"Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia","volume":"5","author":"Rushing","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2019.11.015_bib6","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/1097-0142(19821101)50:9<1683::AID-CNCR2820500904>3.0.CO;2-X","article-title":"Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia","volume":"50","author":"Bolin","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.11.015_bib7","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta analysis of seven randomized trials","volume":"89","year":"1997","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2019.11.015_bib8","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A\u00a0randomized study of interferon-alpha versus interferon alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0037-1963(03)70040-7","article-title":"Interferon alpha for chronic myeloid leukemia","volume":"40","author":"Baccarani","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2019.11.015_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French chronic myeloid leukemia study group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.11.015_bib12","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood.V98.7.2039","article-title":"Chronic myeloid leukemia: current treatment options","volume":"98","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib13","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Drucker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.11.015_bib14","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Goldman","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.11.015_bib15","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","article-title":"Long term survival benefit and improved complete cytogenetic and molecular response rate with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib16","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2003-07-2575","article-title":"Molecular response to imatinib in late chronic phase chronic myeloid leukemia","volume":"103","author":"Rosti","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib17","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.11.015_bib18","volume":"112","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib19","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib20","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib21","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","article-title":"High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.11.015_bib22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.11.015_bib23","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.11.015_bib24","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.11.015_bib25","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.11.015_bib26","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib27","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.11.015_bib28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/bmt.2008.90","article-title":"Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?","volume":"42","author":"Ruiz-Arguelles","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.11.015_bib31","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/cncr.22498","article-title":"Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country","volume":"109","author":"Aziz","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.11.015_bib32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00277-017-3224-2","article-title":"Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience)","volume":"97","author":"Ben Lakhal","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.11.015_bib33","first-page":"31","article-title":"Pattern of adult leukemias at Al-Jomhori Educational Hospital, Sana\u2019a, Yemen","volume":"22","author":"Al-Ghazaly","year":"2005","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.clml.2019.11.015_bib34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2257.2006.00823.x","article-title":"Pattern of haematological diseases diagnosed by bone marrow examination in Yemen: a developing country experience","volume":"28","author":"Al-Ghazaly","year":"2006","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.clml.2019.11.015_bib35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.20428\/yjms.v8i1.678","article-title":"A\u00a0ten year descriptive study of adult leukaemia at Al-Jomhori Teaching Hospital in Sana\u2019a, Yemen","volume":"8","author":"Al-Ghazaly","year":"2014","journal-title":"Yem J Med Sci"},{"key":"10.1016\/j.clml.2019.11.015_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03630269.2012.751033","article-title":"Characteristics of sickle cell anemia in Yemen","volume":"37","author":"Al-Ghazaly","year":"2013","journal-title":"Hemoglobin"},{"key":"10.1016\/j.clml.2019.11.015_bib37","doi-asserted-by":"crossref","first-page":"e2017056","DOI":"10.4084\/mjhid.2017.056","article-title":"Hematological characteristics of Yemeni adults and children with visceral leishmaniasis. Could eosinopenia be a suspicion index?","volume":"9","author":"Al-Ghazaly","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2019.11.015_bib38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib39","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib40","unstructured":"Sokal JE, Cox EB, Baccarani M, et al. Socal score for CML\/ calculate by QxMD. Available at: https:\/\/qxmd.com\/calculate\/calculator_559\/sokal-score-for-cml. Accessed: January 19, 2019."},{"issue":"suppl 2","key":"10.1016\/j.clml.2019.11.015_bib42","doi-asserted-by":"crossref","first-page":"s241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"Hoglund","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.11.015_bib43","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.11.015_bib44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cegh.2016.06.001","article-title":"Demographic factors related to young age at diagnosis of chronic myeloid leukemia in India","volume":"4","author":"Levine","year":"2016","journal-title":"Clin Epidemiol Glob Health"},{"key":"10.1016\/j.clml.2019.11.015_bib45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","article-title":"Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party","volume":"92","author":"Rosti","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.11.015_bib47","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2019.11.015_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jnci.2015.03.004","article-title":"Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: single institution experience","volume":"27","author":"Edesa","year":"2015","journal-title":"J\u00a0Egypt Natl Canc Inst"},{"key":"10.1016\/j.clml.2019.11.015_bib49","doi-asserted-by":"crossref","first-page":"e2017062","DOI":"10.4084\/mjhid.2017.062","article-title":"Outcome of frontline treatment with \u201cgeneric\u201d imatinib in adult patients with chronic myeloid leukemia in Algerian population: a multicenter study","volume":"9","author":"Entasoltan","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2019.11.015_bib50","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib51","doi-asserted-by":"crossref","first-page":"e2015013","DOI":"10.4084\/mjhid.2015.013","article-title":"Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study","volume":"7","author":"Kapoor","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2019.11.015_bib52","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.015_bib53","first-page":"25","article-title":"The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukaemia in the imatinib era","volume":"2","author":"Oyekunle","year":"2012","journal-title":"J\u00a0Hematol Malig"},{"key":"10.1016\/j.clml.2019.11.015_bib54","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.11.015_bib55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1590\/S1807-59322009000800004","article-title":"Influence of late treatment on how chronic myeloid leukemia responds to imatinib","volume":"64","author":"Scerni","year":"2009","journal-title":"Clinics (Sao Paulo)"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019321664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019321664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:35:34Z","timestamp":1730529334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019321664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S2152265019321664"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.11.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}